• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 20
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 20
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    SARS-CoV-2 R&D: Is It Over?

    Sustainability: A New Threat or Opportunity for CDMOs?

    Advanced Therapy Manufacturing

    Advanced Therapy Packaging Trends

    CEO Spotlight: Darren Head
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    iECURE Enters Agreement with Center for Breakthrough Medicines

    CPDC Enters Clinical Manufacturing Deal with CellBion

    Olon to Build New R&D Center in Italy

    Hanmi Fine Chemical Launches CDMO Business

    DFE Pharma Opens India CoE for Fast-Track Formulation Services
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    iECURE Enters Agreement with Center for Breakthrough Medicines

    CPDC Enters Clinical Manufacturing Deal with CellBion

    Olon to Build New R&D Center in Italy

    Hanmi Fine Chemical Launches CDMO Business

    DFE Pharma Opens India CoE for Fast-Track Formulation Services
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Selecting a CMO Partner for Sterile Injectable Manufacturing

    Royalty Pharma and Jefferies Invest $111M in ApiJect

    Cryoport Acquires Cell&Co BioServices for €6.2M

    Challenges of Developing Large Volume Drug/Device Combination Products for Parenteral SC Delivery

    Yourway Adds Capacity for Controlled Ambient Storage
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    CRO Market Insights

    Hanmi Fine Chemical Launches CDMO Business

    DFE Pharma Opens India CoE for Fast-Track Formulation Services

    Helsinn Establishes New R&D Hub in the U.S.

    CureVac, myNEO Partner on Antigen Targets for mRNA-Cancer Vax Development
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    FDA Inspection Trends Update

    Phase-Appropriate cGMP Considerations for Cell and Gene Therapy

    Sustainability: A New Threat or Opportunity for CDMOs?

    In Pursuit of Sustainability: How the Biopharma Industry Can Contribute

    Conducting Clinical Trials During the Pandemic: What Did We Learn?
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Alcami

    Biosynth Carbosynth

    Quotient Sciences

    IDT Biologika

    CMC Pharmaceuticals
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Alcami

    Biosynth Carbosynth

    Quotient Sciences

    IDT Biologika

    CMC Pharmaceuticals
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Podcasts
    • Infographics
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Online Exclusives

    DCAT Week '17 Q&A: API Market Trends

    Minzhang Chen of STA Pharmaceutical discusses the company’s business model, initiatives, and trends driving API development

    Related CONTENT
    • WuXi AppTec
    • WuXi STA Completes Acquisition of BMS Manufacturing Facility
    • WuXi STA Chooses Middletown Delaware for New Pharma Manufacturing Campus
    • WuXi Biologics, WuXi STA Establish WuXi XDC JV
    • Cold-Chain Handling Is Not Just a COVID Vaccine Challenge
    Kristin Brooks, Contract Pharma03.27.17
    STA Pharmaceutical, the small molecule branch of WuXi AppTec, develops NCEs (APIs) for pharma and biopharma companies, providing early and late phase development and manufacture, as well as commercial manufacture. The company only develops patented drugs, and while it is not particularly well known, is currently working on more than 100 APIs (200 inclusive of intermediates). 
     
    Contract Pharma spoke with Minzhang Chen, chief executive officer at STA Pharmaceutical to learn more about the company and API market trends. --KB
     
    Contract Pharma: Please provide a brief background on STA Pharmaceutical and its services
     
    Minzhang Chen: STA is a subsidiary of WuXi AppTec providing a small molecule pharmaceutical development and manufacturing platform serving the life sciences industry. In the past few years, the company has grown very quickly. In 2016, we opened a 39-acre fully integrated process R&D and API manufacturing facility in Changzhou, China as well as a facility to support preclinical and early phase API Process R&D and cGMP production in San Diego, CA. These add to STA’s existing FDA approved facility in Jinshan (Shanghai) and an R&D site in Shanghai. Our customer base is roughly made-up of around 90% pharma and biotech customers from the U.S. and Europe with 10% Chinese innovative drug development companies. Overall in 2016, STA accomplished more than 500 projects including 150 New Chemical Entity APIs under clinical development and more than 30 projects in Phase III or commercial production.
     
    Our integrated Changzhou site is designed to advance our client’s APIs and advanced intermediates through preclinical and clinical development to global commercial launch. Upon completion, the site will employ more than 500 scientists and will add nine pilot and commercial plants with more than 1,500 m3 of reactor volume in total.  The plants will fulfill our customer’s pipeline needs, with many of the programs now entering process validation and commercialization stage, requiring us to add production capacity. In fact, since the Changzhou site opened less than a year ago, we have more than 40 active pharma customers running programs at this site, with 60 APIs and/or intermediates supporting various clinical programs, and one New Chemical Entity API already in commercial production at this site.
     
    CP: What’s the company’s business model?  How does STA set itself apart from other firms?
     
    MC: STA has taken the approach of working with very large numbers of pharma and biotech clients earlier in the development and R&D cycle, and staying with these partners through to commercialization. Unlike some of the other CDMOs, who try to pick up work at a later stage, our strategy is to maintain a huge pipeline of early clinical stage clients, with a view to progressing these into commercial production. So, rather than trying to back-integrate, we are helping our customers from the inception of their product through to launch. This approach has led to a steady pipeline of work entering into commercial production and also means we handled more projects in the R&D stage than other CDMOs.
     
    In the last few years, our commercial manufacturing capacity need has been rising and we are now investing heavily in new manufacturing facilities to meet the demand. Another difference in our strategy compared to many of the other CDMOs, is that we are investing heavily in our own world class facilities rather than through acquisition – which, I think, is a testament to the company’s strength and confidence, new business pipeline and ability to move a large number of development projects into commercial production.
     
    CP: What are some initiatives currently underway?
     
    MC: STA has taken many initiatives in recent years with the aim of becoming an industry leader in “Green Chemistry”.  Our biocatalysis center now owns an in-house library of more than 500 commercial enzymes available for rapid screening.  The team successfully manufactured over 50 programs ranging from kilo to metric ton scale under cGMP using this technology.  We also built a comprehensive flow chemistry platform. To date, we’re fully equipped with various laboratory and plant scale flow chemistry systems to handle some of the most challenging or hazardous chemistries such as photochemistry, ozonolysis, cross-coupling reactions (Negishi and Kumada), reactions with sodium azide, just to name a few examples.  
     
    One of the lesser-reported activities we strive to undertake at STA is to constantly improve the effectiveness of our processes, improve efficiency and reduce waste. Company-wide, in the last several years we have reduced our overall PMI (Process Mass Intensity) index by around 25% each year, and we are targeting another 20% in 2017 – which really would be quite remarkable. It’s a challenge we set for our chemists and manufacturing teams to design “greener” processes for new programs and keep improving the processes we have already developed.
     
     
    CP: What is the company’s strategy for the next five years?
     
    MC: The next five years is going to be a key period for both STA and the wider industry. We are going to continue to invest in enhancing the capability and capacity of our service offerings. We’ve seen increased consolidation among CDMOs, and the market is clearly moving towards providers who can offer a wide range of technical capabilities. Our core strength has been our R&D teams but increasingly we foresee a much greater volume of commercial production at the expanded STA sites. We expect to grow at over a double-digit pace for the next five years as the company fills this capacity.
     
    CP: What market trends are driving API development today?
     
    MC: There are a couple of notable major trends. First, the types of molecules being developed are becoming far more complicated, requiring more advanced chemistries and technologies. This is presenting good opportunities for STA as both biotech and pharma customers need experienced R&D and manufacturing teams working closely together that can deliver these new drug targets faster. CDMOs must adapt to the new paradigms in the market – speed and flexibility will be a major factor in those that fail or succeed. We also saw tightened regulatory oversight from around the globe which is reflected by the increased number of Warning Letters issued by FDA as well as the regulatory “push backs” on the Starting Materials definitions.   
     
     
    CP: Are there certain regulatory/quality control issues the industry continues to face?
     
    MC: What we are seeing is that customers are far more closely attuned to working with CDMOs with the highest standards of manufacturing quality and control. While cost continues to be a factor on decisions, the ability to demonstrate a proven track record of global regulatory approvals, coupled with experience in QbD and continuous improvement, are an essential component of working with an outsourced partner.
     
    At STA, we have an exemplary regulatory record. We’re the first CMC platform in China that passed FDA inspection for new chemical entities. Our Jinshan API facility is also the first contract manufacturing organization in China that is approved to supply APIs and GMP intermediates for branded commercial drugs by regulatory agencies in U.S., Canada, EU, Switzerland, China, Japan, Australia, and New Zealand. Our facilities have also successfully passed quality audits by more than 100 clients worldwide since 2004. Regulatory and quality excellence remain a fundamental part of our growth strategy.
     


     
    Minzhang Chen, CEO at STA Pharmaceutical, a WuXi AppTec Company
    Dr. Chen joined WuXi AppTec in 2008 and currently serves as CEO of STA, the small molecule process development and manufacturing subsidiary of WuXi AppTec. Under his leadership, STA has grown over the past seven years from an early phase process research focused organization to a world leading contract development and manufacturing organization for process R&D and API manufacturing from preclinical to commercial.
     
    Prior to joining WuXi, he served as Director of Technical Operations at Vertex Pharmaceuticals where he led a team who successfully supported the process R&D, API contract manufacturing and commercialization of Incivek. He also worked as a Principle Scientist at Schering-Plough Research Institute before joining Vertex.
    Related Searches
    • Validation
    • pipeline
    • apis
    • API
    Suggested For You
    WuXi AppTec WuXi AppTec
    WuXi STA Completes Acquisition of BMS Manufacturing Facility WuXi STA Completes Acquisition of BMS Manufacturing Facility
    WuXi STA Chooses Middletown Delaware for New Pharma Manufacturing Campus WuXi STA Chooses Middletown Delaware for New Pharma Manufacturing Campus
    WuXi Biologics, WuXi STA Establish WuXi XDC JV WuXi Biologics, WuXi STA Establish WuXi XDC JV
    Cold-Chain Handling Is Not Just a COVID Vaccine Challenge Cold-Chain Handling Is Not Just a COVID Vaccine Challenge
    Tubulis, WuXi Biologics and WuXi STA Form Strategic Pact Tubulis, WuXi Biologics and WuXi STA Form Strategic Pact
    Mogene Mogene
    Vetio Animal Health Vetio Animal Health
    Frontida BioPharm Launches Expansion Efforts Frontida BioPharm Launches Expansion Efforts
    So You Think You Know  All About Excipients? So You Think You Know All About Excipients?
    The FDA and Metrics The FDA and Metrics
    CROs & Next-Gen  Drug Development CROs & Next-Gen Drug Development
    Injectable Drug Delivery Trends Injectable Drug Delivery Trends
    Trump Picks New FDA Commish Trump Picks New FDA Commish
    Reality and Un-Reality:  Continuous Processing in Pharmaceutical Manufacturing Reality and Un-Reality: Continuous Processing in Pharmaceutical Manufacturing

    Related Content

    • WuXi AppTec

      ...
      Daja Herald, Marketing Director 11.22.21

    • Breaking News | Facilities | Industry News
      WuXi STA Completes Acquisition of BMS Manufacturing Facility

      WuXi STA Completes Acquisition of BMS Manufacturing Facility

      State-of-the-art facility in Couvet, Switzerland enhances WuXi STA's drug product capacity in Europe.
      08.03.21

    • Breaking News | Collaborations & Alliances | Facilities | Industry News
      WuXi STA Chooses Middletown Delaware for New Pharma Manufacturing Campus

      WuXi STA Chooses Middletown Delaware for New Pharma Manufacturing Campus

      The CDMO is bringing about 500 jobs to Middletown, with site expected to open in 2024.
      06.29.21


    • Biologics, Proteins, Vaccines | Breaking News | cGMP Manufacture | Industry News
      WuXi Biologics, WuXi STA Establish WuXi XDC JV

      WuXi Biologics, WuXi STA Establish WuXi XDC JV

      To provide contract development and manufacturing of bioconjugates including antibody-drug conjugates (ADCs).
      Kristin Brooks 05.14.21

    • Cold Chain Management
      Cold-Chain Handling Is Not Just a COVID Vaccine Challenge

      Cold-Chain Handling Is Not Just a COVID Vaccine Challenge

      More robust solutions for single-use cold-chain containers made with polytetrafluoroethylene fluoropolymers may be less susceptible to failure and breakage.
      Joe Cintavey, Gore PharmBIO 03.30.21

      Trending
      • How Can Automation Optimize Immunohistochemistry? | Contract Pharma
      • Catalyst Biosciences Sells Complement Portfolio To Vertex Pharmaceuticals | Contract Pharma
      • Corealis CDMO Completes Deal With ArchiMed | Contract Pharma
      • Mirum Pharmaceuticals Acquires San Diego-based Satiogen | Contract Pharma
      • CureVac, MyNEO Partner On Antigen Targets For MRNA-Cancer Vax Development | Contract Pharma
      Breaking News
      • iECURE Enters Agreement with Center for Breakthrough Medicines
      • CPDC Enters Clinical Manufacturing Deal with CellBion
      • Olon to Build New R&D Center in Italy
      • Hanmi Fine Chemical Launches CDMO Business
      • DFE Pharma Opens India CoE for Fast-Track Formulation Services
      View Breaking News >
      CURRENT ISSUE

      May 2022

      • Sustainability and the Biopharma Industry
      • Contract Manufacturing During COVID
      • Orphan Drugs in the United States
      • CEO Spotlight: Peter DeYoung
      • CEO Spotlight: Darren Head
      • Advanced Therapy Packaging Trends
      • Advanced Therapy Manufacturing
      • Sustainability: A New Threat or Opportunity for CDMOs?
      • SARS-CoV-2 R&D

      Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
      You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

      • About Us
      • Privacy Policy
      • Terms And Conditions
      • Contact Us

      follow us

      Subscribe
      Nutraceuticals World

      Latest Breaking News From Nutraceuticals World

      Thorne Relaunches Gut Health Test with Microbiome Wipe
      Alkemist Labs Announces Alkemist Assured Seal and Next Generation Transparency Reports
      GC Rieber Foundations Expand Philanthropic Efforts
      Coatings World

      Latest Breaking News From Coatings World

      Sustainability, Economy are Focus of BCF’s Annual Conference
      Demand for Rhino Shield Increases
      ICP Receives ASC Innovation Award for Spray Foam That Meets Changing Environmental Regulations
      Medical Product Outsourcing

      Latest Breaking News From Medical Product Outsourcing

      New Breast Implant Surgery Guidelines to Enhance Patient Safety
      Rhythm Management Group Debuts RhythmSynergy Tech Platform
      FDA Approves Trial Completion for Virtual Incision's MIRA Platform
      Contract Pharma

      Latest Breaking News From Contract Pharma

      iECURE Enters Agreement with Center for Breakthrough Medicines
      CPDC Enters Clinical Manufacturing Deal with CellBion
      Olon to Build New R&D Center in Italy
      Beauty Packaging

      Latest Breaking News From Beauty Packaging

      K-Beauty Brand Siita Shares Plastic Decomposition Technology with the Beauty Industry
      Shellworks Raises $6.2 Million in Seed Funding
      Ulta Beauty Reports Record First Quarter 2022 Results
      Happi

      Latest Breaking News From Happi

      Honeywell Addresses Critical Issues Such as Sustainability, Workforce Training and Digitalization
      Monat Global Wins Four Stevie Awards in the 20th Annual American Business Awards
      Coty Expands Vegan Beauty Portfolio With New Rimmel Mascara
      Ink World

      Latest Breaking News From Ink World

      Zeller+Gmelin Honored as Berry Global’s 2021 Ink Supplier of the Year
      Paul N. Gardner USA Introduces New PosiTector GLS Gloss Meter
      UK-Based Caps Cases Installs World’s First EFI Nozomi 14000 LED Digital Corrugated Press
      Label & Narrow Web

      Latest Breaking News From Label & Narrow Web

      UPM Raflatac accelerates label growth with acquisition
      Labelexpo Asia 2022 postponed
      Teklynx software helps Top Clean Injection validate labels
      Nonwovens Industry

      Latest Breaking News From Nonwovens Industry

      Rael Raises $35M in Series B Funding
      Schobertechnologies Offers Rotary Web-fed Converting Solutions
      Thorne Relaunches Gut Health Test with Microbiome Wipe
      Orthopedic Design & Technology

      Latest Breaking News From Orthopedic Design & Technology

      Toetal Solutions Raises $1.02 Million in New Financing
      ManaMed's ManaSport Wearable Ultrasound Earns FDA Nod
      Ekso Bionics Names Jerome Wong as Interim CFO
      Printed Electronics Now

      Latest Breaking News From Printed Electronics Now

      onsemi Recognized by Fortune 500 for Its Transformation Journey
      LG Display Presents AI-Driven NFT Artwork on Transparent OLED
      Joe Stockunas Joins SEMI as Americas President

      Copyright © 2022 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

      AD BLOCKER DETECTED

      Our website is made possible by displaying online advertisements to our visitors.
      Please consider supporting us by disabling your ad blocker.


      FREE SUBSCRIPTION Already a subscriber? Login